|Place of Origin:||China|
|Minimum Order Quantity:||Negotiable|
|Packaging Details:||Discreet and tight safe packing for customs pass guaranteed|
|Delivery Time:||Within 24 hours after payment|
|Payment Terms:||T/T, , MoneyGram, Bit-coin|
|Supply Ability:||Mass stock|
|Grade:||Pharmaceutical Grade||Chemical Properties:||Off-White Solid|
anti cancer drugs,
Product name: Gefitinib , Iressa
Alias: GEFITINIB; AKOS 91371; n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; ZD 1839; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-; Gefitinib(TINIBS); Gefitinib, Iressa, ZD1839; Gefitinib Base
CAS RN: 184475-35-2
Molecular formula: C22H24ClFN4O3
Molecular weight: 446.9024
Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nm, in NR6W cells.
|Appearance||Slight white to white crystalline powder||White crystalline powder|
|Identification IR(1)||Conforms to the refence||Conforms to the refence|
|Individual Purity (HPLC )||≤0.20%||0.09%|
Conform with company standard
Gefitinib is a kind of selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
The recommended treatment dose of adult is 250 mg of (1 tablet) with 1 time per day through orally administration, either in empty stomach or together with food.
If you have difficulty in swallowing, you can disperse the tablets into a half cup of drinking water (non-carbonated beverages). Make sure to avoid using other kinds of liquid. Cast tablets into the water and stir until the complete dispersion of the tablet in the water (takes about 10 minutes) without the necessity of crushing. Immediately drink the liquid, and use half glass of water to rinse the cup, drink again. Alternatively, you can also administrate this drug solution through the nose - stomach tube.
There is no necessity in adjusting the administrated dosage of the drug: age, weight, gender, race, renal function, and moderate to severe liver function dysfunction caused by hepatic metastasis.
when patients can't tolerate the diarrhea or skin adverse reactions, you can tackle this issue through short-term suspension (up to 14 days) of the treatment and then restore the dose of 250 mg per day.
|Product name||CAS No.|